the aid library

LIST OPTIONS

Filter

1119

Sort by:

Direction:

Download (941)

View PDF (1221)

National HIV/Syphilis sero-prevalence sentinel survey among pregnant women attending antenatal clinics in Nigeria

Federal Ministry of Health, Dept. of Public Health, National HIVSTI (2005) C1

Download (1134)

View PDF (1648)

Management and Control of Viral Haemorrhagic Fevers and other highly contagious viral pathogens

European Network for Diagnostics of Imported Viral Diseases (2001) C1

Download (699)

View PDF (1560)

District guidelines for yellow fever surveillance

World Health Organization WHO (1998) C_WHO

Download (2483)

View PDF (3134)

Guide OMS pour la préparation et la riposte aux épidémies: Fièvre hémorragique à virus Ebola

World Health Organization (1997)

Download (1250)

View PDF (1782)

WHO guidance: Public health response to biological and chemical weapons

World Health Organization (2004) C_WHO

The message contained in this publication is clear: countries need a public health system that can respond to the deliberate release of chemical and biological agents. Regrettable though this message may be, the use of poison gas in the war between Iraq and the Islamic Republic of Iran in the 19... more

Download (1257)

View PDF (2669)

Prélèvement déchantillons et envoi

Organisation Mondiale de la Santé OMS (1998)

Download (179)

View PDF (148)

Pandemic influenza preparedness framework: partnership contribution high-level implementation plan III 2024-2030

World Health Organization WHO (2023) C_WHO

The Pandemic Influenza Pandemic (PIP) Framework's Partnership Contribution (PC) High-Level Implementation Plan III (HLIP III) outlines the strategy for strengthening global pandemic influenza preparedness from 2024 to 2030. HLIP III takes into consideration the lessons learned from the response to t... more

Download (116)

View PDF (303)

Mapping Antimicrobial Resistance and Antimicrobial Use Partnership (MAAP) Country Report Gabon

Africa Center for Disease Control and Prevention (2023) CC

The Mapping Antimicrobial Resistance and Antimicrobial Use Partnership (MAAP) project has conducted a multi-year, multi-country study that provides stark insights on the under-reported depth of the antimicrobial resistance (AMR) crisis across Africa and lays out urgent policy recommendations to addr... more

Download (156)

View PDF (375)

Cartographie des rapports nationaux du Partenariat sur la résistance aux antimicrobiens et l'utilisation des antimicrobiens (MAAP) Gabon

Africa Center for Disease Control and Prevention (2023) CC

Download (97)

View PDF (276)

Mapping Antimicrobial Resistance and Antimicrobial Use Partnership (MAAP) Country Report Senegal

Africa Center for Disease Control and Prevention (2023) CC

Download (145)

View PDF (120)

Public health resource pack for countries experiencing outbreaks of influenza in animals: revised guidance

World Health Organisation (WHO) (2023) C_WHO

This resource pack was developed for the country offices of the World Health Organization and national Public Health institutions, as an overview of the key information needed for advising their Member States in response to questions raised on human health due to influenza outbreaks or detections in... more

Download (24)

View PDF (15)

From emergency response to long-term COVID-19 disease management - Ending the COVID-19 emergency and transitioning from emergency phase to longer-term disease management: Guidance on calibrating the r

World Health Organization WHO (2023) C_WHO

The key actions, activities, and approaches in this document are organized within each of the 5Cs (see Table 1 in the PDF) and those of the Strategic preparedness and response plan (SPRP) pillars as follows: National action plan key activities, prioritized for the current context and the current ... more

Download (135)

View PDF (118)

Guidance for country validation of viral hepatitis elimination and path to elimination

World Health Organization WHO (2023) C_WHO

Building on the 2021 Interim guidance, this second version and update, incorporates the lessons and feedback from the hepatitis pilots that successfully demonstrated the feasibility of measuring hepatitis B and C impact targets to demonstrate elimination, whilst highlighting challenges caused by hig... more

Download (239)

View PDF (322)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (201)

View PDF (174)

A checklist for respiratory pathogen pandemic preparedness planning

World Health Organization WHO (2023) C_WHO

This checklist is an operational tool to help national authorities develop or revise national respiratory pathogen (inclusive of influenza and coronaviruses) pandemic preparedness plans.

Download (112)

View PDF (95)

Laboratory manual for yellow fever
recommended

World Health Organization WHO (2024) C_WHO

This WHO laboratory manual provides the most up to date methods and procedures for the laboratory identification of yellow fever virus infection in humans. It provides guidance on the establishment and maintenance of an effective laboratory providing routine surveillance testing for yellow fever, wh... more

Download (99)

View PDF (93)

Framework of a national program for preventing and controlling diseases caused by respiratory viruses with epidemic and pandemic potential, Washington, D.C., 2024

Pan American Health organization PAHO; World Health Organization WHO (2024) C_WHO

At the global, national, and regional levels, there are several guidelines and guides regarding the preparedness, prevention, surveillance, and control of diseases caused by respiratory viruses; most initiatives focus on specific virus events or cases. During the coronavirus disease 2019 (COVID-19) ... more

Download (95)

View PDF (50)

Variole du singe (monkeypox)

Institut de Médecine Tropicale, Université de Bordeau (2024) C2

2024

Download (28)

View PDF (90)

UNAIDS Terminology Guidelines

UNAIDS (2024) CC

Language influences the way we think, how we perceive reality, and how we behave. With respect to HIV, language can embody stigma and discrimination, which impacts access to testing, acquisition of HIV, and engagement with treatment. Language plays a role in supporting respect and empowerment of ind... more

Download (16)

View PDF (13)

Annual Report: Global Polio Eradication Initiative

World Health Organisation (WHO) (2024) CC

The key to a lasting world free of all forms of poliovirus lies in rapidly interrupting all remaining endemic transmission of WPV in the endemic areas of Pakistan and Afghanistan. This is the only way to ensure that such strains do not re-emerge globally through international spread. It lays the cor... more

Laboratory manual for yellow fever recommended

Laboratory manual for yellow fever
recommended